Leukocyte immunoglobulin-like receptor B2 : A promising biomarker for colorectal cancer

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved..

According to the latest global cancer statistics, colorectal cancer (CRC) has emerged as the third most prevalent malignant tumor across the globe. In recent decades, the medical field has implemented several levels of CRC screening tests, encompassing fecal tests, endoscopic examinations, radiological examinations and blood tests. Previous studies have shown that leukocyte immunoglobulin-like receptor B2 (LILRB2) is involved in inhibiting immune cell function, immune evasion, and promoting tumor progression in acute myeloid leukemia and non-small cell lung cancer. However, its interaction with CRC has not been reported yet. Recently, a study published in the World Journal of Gastroenterology revealed that LILRB2 and its ligand, angiopoietin-like protein 2, are markedly overexpressed in CRC. This overexpression is closely linked to tumor progression and is indicative of a poor prognosis. The study highlights the potential of utilizing the concentration of LILRB2 in serum as a promising biomarker for tumors. However, there is still room for discussion regarding the data processing and analysis in this research.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:30

Enthalten in:

World journal of gastroenterology - 30(2024), 4 vom: 28. Jan., Seite 421-423

Sprache:

Englisch

Beteiligte Personen:

Zhao, Wen-Zhuo [VerfasserIn]
Wang, Hong-Gang [VerfasserIn]
Yang, Xiao-Zhong [VerfasserIn]

Links:

Volltext

Themen:

Angiopoietin-like protein 2
Biomarkers, Tumor
Colorectal cancer
Journal Article
LILRB2 protein, human
Leukocyte immunoglobulin-like receptor B2
Membrane Glycoproteins
Noninvasive screening biomarker
Receptors, Immunologic
Therapeutic target

Anmerkungen:

Date Completed 06.02.2024

Date Revised 06.02.2024

published: Print

Citation Status MEDLINE

doi:

10.3748/wjg.v30.i4.421

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM368024385